The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 461-468

  Davidson, David ^a   Wang, Yunzhe ^a   Aloyz, Raquel ^a   Panasci, Lawrence ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Colon cancer; Irinotecan; PARP; PARP inhibitor; SN38; VE 821

Indexed keywords

FIRTECAN; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OXALIPLATIN; VELIPARIB;

ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; IC 50; IN VITRO STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZIMIDAZOLES; BLOTTING, WESTERN; CAMPTOTHECIN; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; TUMOR CELLS, CULTURED;

EID: 84879555636     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9886-7     Document Type: Article

References (48)

1. Raftery L, Goldberg RM (2010) Optimal delivery of cytotoxic chemotherapy for colon cancer. Cancer J 16:214-219
2. Edwards SL (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111-1115
3. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615-627
4. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23
5. Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG (2002) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 100:224-229
6. Amrein L, Loignon M, Goulet A-C, Dunn M, Jean-Claude B, Aloyz R, et al. (2007) Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. J Pharmacol Exp Ther 321:848-855
7. Davidson D, Coulombe Y, Martinez-Marignac V, Amrein L, Grenier J, Hodkinson K, et al. (2012) Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs 30:1248-1256
8. Davidson D, Grenier J, Martinez-Marignac V, Amrein L, Shawi M, Tokars M, et al. (2012) Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. Invest New Drugs 30:1736-1742
9. Nutley BP, Smith NF, Hayes A, Kelland LR, Brunton L, Golding BT, et al. (2005) Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer 93:1011-1018
10. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. (2007) ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models. Clin Cancer Res 13:2728-2737
11. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, et al. (2009) Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 8:2232-2242
12. Ji J, Lee M, Kadota M, Zhang Y, Parchment R, Tomaszewski JE, et al. (2011) Pharmacodynamic and pathway analysis of three presumed inhibitors of poly (ADP-ribose) polymerase: ABT-888, AZD2281, and BSI201. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 April 2-6; Orlando, FL. Philidelphia, PA: American Association of Cancer Research
13. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27:2705-2711
14. Curtin NJ (2005) PARP inhibitors for cancer therapy. Expert Rev Mol Med 7:1-20
15. Heacock ML, Stefanick DF, Horton JK, Wilson SH (2010) Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks. DNA Repair 9:929-936
16. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Molecular Oncology; 5:387-393.
17. Javle M, Curtin NJ (2011) The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 105:1114-1122
18. Kummar S, Chen A, Parchment R, Kinders R, Ji J, Tomaszewski J, et al. (2012) Advances in using PARP inhibitors to treat cancer. BMC Med 10:25
19. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293-301
20. Sousa FG, Matuo R, Soares DG, Escargueil AE, Henriques JAP, Larsen AK, et al. (2012) PARPs and the DNA damage response. Carcinogenesis
21. Tentori L, Graziani G (2005) Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52:25-33
22. Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ (2011) Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochem J 436:671-679
23. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, et al. (2009) A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 27:756-763
24. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. (2008) Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14:7917-7923
25. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112-1116
26. Berenbaum M (1992) Letter Correspondence re: "Greco, et al., Applications of a New Approach for the Quantitation of Drug Synergism to the Combination of c/s-Diamminedichloroplatinum and 1-tf-D-Arabinofuranosylcytosine. Cancer Res 50: 5318-5327, 1990.". Cancer Res 52:4558-4565
27. Xu Z-Y, Loignon M, Han F-Y, Panasci L, Aloyz R (2005) Xrcc3 Induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther 314:495-505
28. Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, et al. (2006) Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 20:1709-1711
29. Smith J, Mun Tho L, Xu N, A. Gillespie D. The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer. In: George FVW, George K, editors. Advances in Cancer Research: Academic Press; 2010. p. 73-112.
30. Shaheen M, Allen C, Nickoloff JA, Hromas R (2011) Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 117:6074-6082
31. Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, et al. (2012) Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem 287:4198-4210
32. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244
33. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079-17084
34. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. (2009) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512-2519
35. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134
36. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921
37. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, et al. (2010) Therapeutic potential of Poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103:334-346
38. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917
39. Drew Y, Mulligan EA, Vong W-T, Thomas HD, Kahn S, Kyle S, et al. (2011) Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2. J Natl Cancer Inst 103:334-346
40. Rudolf E, Rudolf K, Cervinka M (2011) Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells. Apoptosis 16:1-12
41. Zuco V, Benedetti V, Zunino F (2010) ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968. Cancer Lett 292:186-196
42. Schwartz GK (2005) Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol 23:4499-4508
43. Poele RH, Joel SP (1999) Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. Br J Cancer 81:1285-93
44. Elmageed A, Zakaria Y, Amarjit NS, Errami Y, Zerfaoui M (2012) The Poly(ADP-ribose) polymerases (PARPs): New roles in intracellular transport. Cell Signal 24:1-8
45. Williamson CT, Kubota E, Hamill JD, Klimowicz A, Ye R, Muzik H, et al. (2012) Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med 4:515-527
46. Kedar PS, Stefanick DF, Horton JK, Wilson SH (2008) Interaction between PARP-1 and ATR in mouse fibroblasts is blocked by PARP inhibition. DNA Repair 7:1787-1798
47. Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, et al. (2011) Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle 10:4074-4082
48. LoRusso JJ, Heilbrun LK, Shapiro G, Sausville EA, Boerner SA, Smith DW, et al. (2011) Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 April 2-6; Orlando, FL. Philidelphia, PA: American Association of Cancer Research